EUROPEAN MEETING ON HEPATITIS CURE & E u r … · MEETING PROSPECTUS 1ST EUROPEAN MEETING ON HepCure E u r o p e a n FRANKFURT, GERMANY • 9 - 10 SEPTEMBER 2015 HEPATITIS CURE &

www.virology-education.com

MEETING PROSPECTUS

1ST EUROPEAN MEETING ON

HepCure

European

FRANKFURT, GERMANY • 9 - 10 SEPTEMBER 2015

HEPATITIS CURE & ERADICATION

HepCure

European

21st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany

CONTENT

Workshop description ........................................................................... 4

Background .............................................................................................4

Meeting Objectives ..................................................................................4

Format ....................................................................................................4

Unique Meeting Features .......................................................................4

Target audience ......................................................................................4

Organizing Committee .......................................................................... 5

Scientific Committee ............................................................................ 6

Program outline 2015 ........................................................................... 7

Meeting demographics 2014 ................................................................ 8

Participants’ feedback 2014 .................................................................. 9

HepCure

European


INTRODUCTION

It is our pleasure to invite you for the 1st European Hepatitis Cure & Eradication meeting, which will take place in Frankfurt, Germany on 9 and 10 September 2015.

The field of Hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.

On 9 & 10 september 2015, we will be organizing an international platform to decrease the burden of the disease, to simplify treatment and to cure and eradicate Hepatitis, involving many prominent stakeholders. This public health program addresses awareness and underdiagnosis and undertreatment of viral hepatitis. This state-of-the-art meeting will take place in Frankfurt, Germany

The format of this workshop will consist of a one-and-a-half day translational meeting with state-of-the-art lectures, roundtable discussions and debates. In order to ascertain an interactive workshop setting, much time will be allocated to Q&A and discussion.

This meeting prospectus is designed in order to provide information on the meeting set up and program. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation.

The Organizing Committee

HepCure

European


WORKSHOP DESCRIPTION

BACKGROUNDThe field of Hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.

In order to reach this end goal of cure for Hepatitis, many studies still need to be performed and interpreted. Therefore, to enhance this field of research, we feel there is a need for a state of the art, independent and interactive platform for scientific exchange between hepatitis experts worldwide.

Certainly investigators have the possibility to submit their research in this area to major international conferences, but there is usually limited time for in-depth discussion and debate among experts on new data and their implications.

Goal: defining the pathway forward to cure and eradicate viral hepatitis from the world

MEETING OBJECTIVES• Identify the roadblocks and the challenges to come to an European approach to cure and eradicate viral hepatitis.

• Identify the needs from the public health perspective

• Get a cross-disciplinary discussion started

• Create a platform for collaboration and national action plans.

FORMATThe format of this workshop will consist of a one-and-a-half day translational meeting with invited lectures. In order to ascertain an interactive workshop setting, much time will be allocated to Q&A sessions, roundtable discussions and debates.

UNIQUE MEETING FEATURESThe many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.

In order to reach this end goal of cure for Hepatitis, many studies still need to be performed and interpreted. The International Hepatitis Cure & Eradication Meeting offers a unique platform to discuss what needs to be done now in order to cure and eradicate Hepatitis in the future.

TARGET AUDIENCEThe 1st European Hepatitis Cure & Eradication Meeting 2015 brings together clinicians involved in daily care, academic researchers, policy makers and industry representatives supporting the goal of this meeting.

HepCure

European


ORGANIZING COMMITTEE

HATZAKIS ANGELOS, MD, PHD

University of Athens, Greece

CARLO PERNO, MD, PHD

University of Rome Tor Vergata, Italy

JEAN-MICHEL PAWLOTSKY, MD, PHD

Hôpital Henri Mondor, France

HARRY JANSSEN, MD

University of Toronto, Canada

GRAHAM FOSTER, FRCP, PHD

Queen Mary, University of London United Kingdom

HEINER WEDEMEYER, MD

Medical School Hannover, Germany

STEFAN ZEUZEM, MD

JW Goethe University Hospital, Germany

CHARLES BOUCHER, MD, PHD

Erasmus Medical Center Rotterdam, the Netherlands

HepCure

European


SCIENTIFIC COMMITTEE

Robert Brown ................................................................. University of Missouri, School of Medicine, USA

Maria Butí ...................................................................................................... Hospital Vall’ Hebron, Spain

Milagros Davalos ............................................................ Universidad de Ciências Aplicadas (UCP), Peru

Raffaele De Francesco ...........................................................................................Fondazione INGM, Italy

Rafael Esteban ................................................................................................ Hospital Vall’Hebron, Spain

Peter Ferenci ................................................................................................ University of Vienna, Austria

Margaret Hellard ............................ Burnet Institute for Medical Research and Public Health, Australia

Marina Klein ................................................................................McGillUniversity Health Centre, Canada

Mel Krajden ..................................................................................BC Centre for Disease Control, Canada

Karine Lacombe .........................Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, France

Geoff McCaughan ........................................ University of Sydney Royal Prince Alfred Hospital, Australia

Mark Nelson ...........................................................Chelsea and Westminster Hospital, United Kingdom

Jean-Michel Pawlotsky .............................................. Hôpital Henri Mondor, Université Paris XII, France

Stanislas Pol .......................................................................................................... Hôpital Cochin, France

Massimo Puoti ..................................................................................................University of Brescia, Italy

Robert Ralston .........................................................................University of Kansas Medical Center, USA

Charles Rice ....................................................................................................Rockefeller University, USA

Dominique Salmon ................................................................................................ Hôpital Cochin, France

Mauro Schechter ...................................................................Federal University of Rio de Janeiro, Brazil

Vincent Soriano ................................................................................................... Hospital Carlos III, Spain

James Trotter ................................................................................ Baylor University Medical Center, USA

Fu-Sheng Wang................................................................................................Beijing 302 Hospital, China

Hui Zhuang ..................................................................... Peking University Health Science Centre, China

Fabien Zoulim ...................................................................................................................INSERM, France

HepCure

European


PROGRAM 2015

PROGRAMThe program is currently under development.

The aim of the Organizing Committee is to intermix basic science, clinical medicine and public health issues within the sessions.

This format will emphasize the importance of a broader cohesive response, ensuring that all key holders hear and understand the breadth of cure and eradication of viral hepatitis.

HepCure

European


MEETING DEMOGRAPHICS 2014

NUMBER OF PARTICIPANTS146 participants from 14 countries attended the meeting.

The geographical distribution of participants is as follows:

Australia 3

Austria 1

Belgium 1

Canada 112

China 1

Egypt 1

Germany 2

Italy 2

Japan 1

Nigeria 1

Switzerland 2

The Netherlands 5

United Kingdom 4

USA 10

PROFESSIONAL BACKGROUNDMain activity Mainly employed by:

Area of expertise:

HepCure

European


PARTICIPANTS’ FEEDBACK 2014

This is the evaluation report of the 1st Hepatitis Cure & Eradication Meeting, held on 5 - 6 November 2014 in Toronto, Canada. The Organizing Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects.

On the first day 51 participants completed the evaluation form (35%). On the second day the organizers have been able to collect 72 completed forms (49%).

PERSONAL BENEFITS97,5% of the respondents indicated they will recommend this workshop to their colleagues. Whether they will attend again mainly depends on the location of next year’s edition:

I plan to attend this workshop again next year, if it is being organized prior to the AASLD: 83,1% I plan to attend this workshop again next year, if it is being organized as a stand-alone meeting (in Europe): 43,2% I plan to attend this workshop again next year, if it is being organized as a stand-alone meeting (in North-America): 78,8%

CONTENTVery much

agree

Agree Neutral Disagree Very much

disagree

The content of the meeting met my expectations 44,3% 45,7% 8,6% 1,4% 0,0%

Sufficient time allocated for discussion during the meeting 60,9% 33,3% 2,9% 2,9% 0,0%

The allocated time per presentation was sufficient 57,7% 36,6% 4,2% 1,4% 0,0%

I perceived no commerial bias at the workshop 58,0% 30,4% 8,7% 0,0% 0,0%

HepCure

European



LECTURES

WEDNESDAY 5 NOVEMBER Opening session

Keynote Lecture: The Evolution of Treating Viral Hepatitis

R. Schinazi

Excellent Good Average Fair Poor

Content 51,2% 39,5% 7% 2,3% 0,0%

Presentation 42,9% 42,9% 11,9% 2,4% 0,0%

Towards a cure for Hepatitis B: Inspiration from HIV

D. Hazuda


Content 34,1% 45,5% 13,6% 6,8% 0,0%

Presentation 37,2% 37,2% 18,6% 7,0% 0,0%

Session 1: Hepatitis B – from Control to Cure (part 1)

State of the Art of Hepatitis B Treatment

P. Lampertico


Content 64,6% 31,3% 4,2% 0,0% 0,0%

Presentation 72,3% 23,4% 4,3% 0,0% 0,0%

New HBV Treatment Options on the Horizon

H. Janssen


Content 49,0% 44,9% 6,1% 0,0% 0,0%

Presentation 50,0% 43,8% 6,3% 0,0% 0,0%

Does Viral Cure Prevent HCC Development

H. Chan


Content 56,3% 31,3% 12,5% 0,0% 0,0%

Presentation 51,1% 38,3% 8,5% 2,1% 0,0%

Session 2: Hepatitis B – from Control to Cure (part 2)

How to Achieve Cure in HBV: A Virological Perspective

S. Locarnini


Content 61,7% 31,9% 4,3% 2,1% 0,0%

Presentation 52,1% 39,6% 8,3% 0,0% 0,0%

How to Achieve Cure in HBV: An Immunological Perspective

A. Gehring


Content 68,1% 25,5% 6,4% 0,0% 0,0%

Presentation 70,2% 25,5% 4,3% 0,0% 0,0%

HepCure

European



How to Achieve Cure in HBV: A Clinical Perspective

H. Wedemeyer


Content 68,9% 22,2% 8,9% 0,0% 0,0%

Presentation 68,9% 20,0% 8,9% 2,2% 0,0%

THURSDAY 6 NOVEMBER

Session 3: Hepatitis C – Curing the Patient (part 1)

Current Treatment Challenges

T. Berg


Content 34,9% 50,8% 14,3% 0,0% 0,0%

Presentation 32,8% 51,6% 15,6% 0,0% 0,0%

Treatment in Special Clinical Populations

J. Feld


Content 62,1% 30,3% 7,6% 0,0% 0,0%

Presentation 64,6% 29,2% 6,2% 0,0% 0,0%

Session 4: Hepatitis C – Curing the Patient (part 2)

An HCV Vaccine: Can We Get There?

A. Cox


Content 58,2% 28,4% 13,4% 0,0% 0,0%

Presentation 55,9% 35,3% 8,8% 0,0% 0,0%

Role of Virus Control in Development of HCC

M. Sherman


Content 29,0% 52,2% 13,0% 5,8% 0,0%

Presentation 33,3% 46,4% 14,5% 5,8% 0,0%

Session 5: From Cure to Eradication

Current Prevention Strategies of Viral Hepatitis

K. Mitruka


Content 45,7% 37,1% 17,1% 0,0% 0,0%

Presentation 47,1% 40,0% 12,9% 0,0% 0,0%

Global Underdiagnosis of Viral Hepatitis M. Krajden


Content 37,1% 45,7% 15,7% 1,4% 0,0%

Presentation 35,7% 45,7% 17,1% 1,4% 0,0%

HepCure

European


Linkage of Care

S. Mehta


Content 62,9% 24,3% 12,9% 0,0% 0,0%

Presentation 65,2% 26,1% 8,7% 0,0% 0,0%

Session 6: Treatment as Prevention

Experience in HIV

J. Montaner


Content 49,3% 34,3% 16,4% 0,0% 0,0%

Presentation 53,0% 33,3% 13,6% 0,0% 0,0%

Challenges in HBV

H. Chan


Content 33,8% 44,6% 18,5% 3,1% 0,0%

Presentation 34,4% 48,4% 17,2% 0,0% 0,0%

Challenges in HCV

G. Dore


Content 55,4% 35,4% 9,2% 0,0% 0,0%

Presentation 54,7% 34,4% 10,9% 0,0% 0,0%

Session 7: Delivering Therapy on an Individual & Society Level

Integrative talk

C. Gore


Content 49,2% 39,0% 11,9% 0,0% 0,0%

Presentation 50,0% 43,1% 6,9% 0,0% 0,0%

The Role of the WHO

S. Wiktor


Content 40,4% 43,9% 15,8% 0,0% 0,0%

Presentation 37,5% 51,8% 10,7% 0,0% 0,0%

The Role of the Pharmaceutical industry J. Rooney


Content 35,8% 39,6% 18,9% 0,0% 5,7%

Presentation 34,0% 39,6% 20,8% 1,9% 3,8%

The Role of the Medical community

G. Dusheiko


Content 36,7% 38,8% 20,4% 4,1% 0,0%

Presentation 38,8% 28,6% 28,6% 4,1% 0,0%

The Role of the Medical community

M. El-Sayed


Content 68,8% 22,9% 4,2% 4,2% 0,0%

Presentation 71,4% 18,4% 6,1% 4,1% 0,0%

HepCure

European


The Role of the Patients

C. Gore


Content 44,9% 32,7% 18,4% 4,1% 0,0%

Presentation 42,9% 34,7% 20,4% 2,0% 0,0%

The Role of the CDC USA

K. Mitruka


Content 47,9% 31,3% 18,8% 2,1% 0,0%

Presentation 44,7% 34,0% 19,1% 2,1% 0,0%

Presentation of the Toronto Declaration on Global Eradication of Hepatitis

J. Feld


Content 65,8% 28,9% 5,3% 0,0% 0,0%

Presentation 63,2% 28,9% 7,9% 0,0% 0,0%

Documents

EUROPEAN MEETING ON HEPATITIS CURE & E u r … · MEETING PROSPECTUS 1ST EUROPEAN MEETING ON HepCure E u r o p e a n FRANKFURT, GERMANY • 9 - 10 SEPTEMBER 2015 HEPATITIS CURE &